Precision BioSciences, Inc. (DTIL)
Automate Your Wheel Strategy on DTIL
With Tiblio's Option Bot, you can configure your own wheel strategy including DTIL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DTIL
- Rev/Share 5.5037
- Book/Share 5.3096
- PB 0.9662
- Debt/Equity 0.0277
- CurrentRatio 6.6249
- ROIC -0.3888
- MktCap 56882640.0
- FreeCF/Share -6.322
- PFCF -0.9683
- PE -2.1681
- Debt/Assets 0.011
- DivYield 0
- ROE -0.3585
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | DTIL | BMO Capital Markets | Market Perform | Outperform | -- | $34 | Jan. 10, 2025 |
News
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Precision BioSciences (DTIL) came out with a quarterly loss of $2.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.35 per share a year ago.
Read More
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (.
Read More
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will present initial safety data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV program for the treatment of chronic hepatitis B during a late breaking poster presentation at the European Association for the Study of the Liver.
Read More
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that five abstracts detailing Precision's wholly owned or partnered programs have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 13-17,.
Read More
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.
Read More
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Published: February 19, 2025 by: Benzinga
Sentiment: Positive
On Wednesday, Precision BioSciences, Inc. DTIL revealed initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial.
Read More
About Precision BioSciences, Inc. (DTIL)
- IPO Date 2019-03-28
- Website https://www.precisionbiosciences.com
- Industry Biotechnology
- CEO Mr. Michael Amoroso
- Employees 108